{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:35:40Z","timestamp":1787654140019,"version":"build-2736575974"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Females with haemophilia A (HA [FHAs]) and HA carriers (HACs) have an increased risk of bleeding and complications compared to the general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To examine the characteristics, billed annualised bleed rates (ABR<jats:sub>b<\/jats:sub>), costs and healthcare resource utilisation for males with HA (MHAs), FHAs and HACs in the United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were extracted from the IBM\u00ae MarketScan\u00ae Research Databases (Commercial and Medicaid) for claims during the index period (July 2016 to September 2018) and analysed across MHAs, FHAs and HACs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Dual diagnosis females (DDFs; both HA and HAC claims) were grouped as a separate cohort. MHAs were generally younger than females (all cohorts) by up to 19 years (Commercial) and 23 years (Medicaid). ABR<jats:sub>b<\/jats:sub>\u00a0&gt;0 was more frequent in females. Factor VIII claims were higher for MHAs versus female cohorts. Joint\u2010related health issues were reported for 24.4 and 25.6% (Commercial) and 29.3 and 26.6% (Medicaid) of MHAs and FHAs, respectively; lower rates were reported in the other two cohorts. Heavy menstrual bleeding claims occurred for approximately a fifth (Commercial) to a quarter (Medicaid) of female cohorts. All\u2010cause emergency department and inpatient visits in FHAs and DDFs were similar to, or more frequent than, those in MHAs; bleed\u2010related inpatient visits were infrequent. In MHAs (Commercial), mean all\u2010cause total costs ($214,083) were higher than in FHAs ($40,388), HACs ($15,647) and DDFs ($28,320) with similar trends for Medicaid patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>FHAs and HACs may be undermanaged and undertreated. Further research is needed to fully understand these cohorts' bleeding rates, long\u2010term complications and costs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14794","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T14:23:30Z","timestamp":1683383010000},"page":"809-818","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real\u2010world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3672-8741","authenticated-orcid":false,"given":"Katharine","family":"Batt","sequence":"first","affiliation":[{"name":"Sprouts Consulting Ltd.  Raleigh North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3357-1486","authenticated-orcid":false,"given":"Shan","family":"Xing","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc.  Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-9086","authenticated-orcid":false,"given":"Maja","family":"Kuharic","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc.  Lexington Massachusetts USA"},{"name":"Department of Pharmacy Systems, Outcomes and Policy University of Illinois at Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9961-4576","authenticated-orcid":false,"given":"Michael","family":"Bullano","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc.  Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-568X","authenticated-orcid":false,"given":"Jorge","family":"Caicedo","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc.  Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1948-5135","authenticated-orcid":false,"given":"Sreya","family":"Chakladar","sequence":"additional","affiliation":[{"name":"Complete HEOR Solutions (CHEORS)  North Wales Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6834-318X","authenticated-orcid":false,"given":"Riddhi","family":"Markan","sequence":"additional","affiliation":[{"name":"Complete HEOR Solutions (CHEORS)  North Wales Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8479-2775","authenticated-orcid":false,"given":"Sepehr","family":"Farahbakhshian","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc.  Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"issue":"5","key":"e_1_2_12_2_1","first-page":"s126","article-title":"Economic costs of hemophilia and the impact of prophylactic treatment on patient management","volume":"22","author":"Chen SL","year":"2016","journal-title":"Am J Manag Care"},{"issue":"6","key":"e_1_2_12_3_1","first-page":"S123","article-title":"Hemophilia in the managed care setting","volume":"21","author":"Dalton DR","year":"2015","journal-title":"Am J Manag Care"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15397"},{"key":"e_1_2_12_5_1","unstructured":"CDC.Data and statistics on hemophilia in the United States. Accessed August 11 2022.https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/data.html"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14094"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02210.x"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3879"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13423"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13089"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12468"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14403"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.4018\/IJHISI.2018040101"},{"key":"e_1_2_12_15_1","unstructured":"IBM Corporation.IBM\u00ae MarketScan\u00ae Research Databases for life sciences researchers.2021. Accessed September 28 2022.https:\/\/www.ibm.com\/downloads\/cas\/OWZWJ0QO"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4758.4758"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13220"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13502"},{"key":"e_1_2_12_20_1","unstructured":"National Hemophilia Foundation.Guidelines for pregnancy and perinatal management of women with inherited bleeding disorders and carriers of hemophilia A or B.2021. Accessed September 29 2022.https:\/\/www.hemophilia.org\/healthcare\u2010professionals\/guidelines\u2010on\u2010care\/masac\u2010documents\/masac\u2010document\u2010265\u2010masac\u2010guidelines\u2010for\u2010pregnancy\u2010and\u2010perinatal\u2010management\u2010of\u2010women\u2010with\u2010inherited\u2010bleeding\u2010disorders\u2010and\u2010carriers\u2010of\u2010hemophilia\u2010a\u2010or\u2010b"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.07.010"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.04.024"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14514"},{"key":"e_1_2_12_24_1","volume-title":"Prevalence of Prescription Pain Medication Use Among Adults: United States, 2015\u20132018. NCHS Data Brief, No 369","author":"Hales CM","year":"2020"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.5435\/00124635-200700001-00007"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000337"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb00815.x"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.7.632"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13831"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2019.01.069"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-22-0114"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.32669"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05439-z"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12580"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S325031"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.04.048"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1673354"}],"updated-by":[{"DOI":"10.1111\/hae.14975","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000}}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T14:07:18Z","timestamp":1716905238000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/hae.14794"],"URL":"https:\/\/doi.org\/10.1111\/hae.14794","archive":["Portico"],"relation":{"correction":[{"id-type":"doi","id":"10.1111\/hae.14975","asserted-by":"object"}]},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2022-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}